Eli Lilly Gets FDA Approval for Zepbound

Lilly Rises on FDA Approval of Weight-Loss Drug Zepbound for Sleep Apnea
Key Takeaways Eli Lilly's Zepbound has been approved by the Food and Drug Administration (FDA) as a treatment for adults with sleep apnea and obesity, the drugmaker said after the bell Friday.Trials of the Lilly drug found that it helped reduce the number of breathing disruptions in an average night of sleep.
The FDA just approved Eli Lilly's Zepbound for sleep apnea — and Medicare coverage could be next
Eli Lilly (LLY) announced today that its blockbuster weight-loss drug Zepbound was approved by the U.S. Food and Drug Administration (FDA) as the first prescription drug to help alleviate moderate-to-severe obstructive sleep apnea (OSA) for adults with obesity.
FDA approves Eli Lilly’s obesity medication for obstructive sleep apnea
The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe obstructive sleep apnea for people with obesity.
Sleep Apnea Device Maker Stocks Slide on FDA Ruling for Eli Lilly's Zepbound
Key Takeaways Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat moderate-to-severe obstructive sleep apnea in adults with obesity.
Lilly’s Zepbound Snags First Ever Sleep Apnea Drug Approval
The mega-blockbuster weight loss GLP-1 drug is now also approved to treat obstructive sleep apnea in adults with obesity, in combination with diet and exercise.
FDA approves weight-loss drug to treat obstructive sleep apnea
Even before the FDA approval, some doctors have been prescribing weight-loss drugs to people with sleep apnea.
Lilly Obesity Drug Gets First US Approval for Sleep Apnea
Eli Lilly & Co.’s weight-loss shot Zepbound won approval in the US as the first drug to treat sleep apnea, opening the door for broader insurance coverage of the blockbuster medicine.
Off-brand versions of Lilly weight loss drug must be pulled off market, could mean higher prices
The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...
FDA says the Zepbound shortage is over. Here's what that means for compounding pharmacies, patients who used off-brand versions
The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next two to three months.
Does This News From the FDA Make Eli Lilly a Buy for 2025?
In a recent head-to-head study involving Novo Nordisk 's Wegovy, Zepbound came out on top, resulting in average weight loss ...
Alaska Dispatch News27mOpinion
Opinion: We’ve accepted Wegovy and Zepbound. The next phase is harder.
An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...
NBC 10 Philadelphia5d
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.
The Food and Drug Administration approved Eli Lilly's blockbuster weight loss drug Zepbound for treating patients with the most common sleep-related breathing disorder. The weekly injection is ...
These Stocks Are Moving the Most Today: Honda, Qualcomm, Eli Lilly, ResMed, Tesla, Walmart, Rumble, and More
Honda and Nissan begin merger talks with a plan for the combination to be completed in 2026, Qualcomm scores a victory in its ...
Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and Viking Stocks Are Up
As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.